(Q35007569)

English

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Mark S Berger

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Lance H Leopold

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

James A Dowell

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Joan M Korth-Bradley

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Matthew L Sherman

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

395-406

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of Therapy for Acute Myeloid Leukemia in First Relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-cont

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reinduction chemotherapy for acute nonlymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of adult acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New chemotherapeutic agents in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of acute myeloid leukemia in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1020658028082

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35007569&oldid=2197143580"